Hematological response in patients with paroxysmal nocturnal hemoglobinuria treated with C5-inhibitor

Cover Page

Cite item

Full Text

Abstract

Background. Paroxysmal nocturnal hemoglobinuria is a rare clonal disease of the hematopoietic system, with the key manifestations of hemolytic anemia, a high thrombosis rate, and bone marrow failure. Despite the high efficacy of C5‑inhibitors in intravascular hemolysis cessation, a significant proportion of patients remain anemic. Causes of a sub‑optimal response may include C3‑mediated extravascular (intracellular) hemolysis, residual intravascular hemolysis, or bone marrow failure.

Aim. To analyze the results of pathogenetic therapy in patients with paroxysmal nocturnal hemoglobinuria.

Materials and methods. The study included 55 patients with paroxysmal nocturnal hemoglobinuria receiving complement C5 inhibitors for at least 6 months. Results. Suboptimal hematological response was observed in 31/55 (56 %) patients. The most common cause of anemia in the partial response group was C3‑mediated extravascular hemolysis in 8/10 (80 %), while bone marrow failure predominated (57 %) in the minor response group.

Conclusion. The study showed a high frequency of suboptimal response to pathogenetic therapy and necessity of ac‑
curate determination of leading cause of persistent anemia in order to modify therapy or switch to other drugs.

About the authors

V. D. Latyshev

National Medical Research Center for Hematology, Ministry of Health of Russia

Author for correspondence.
Email: LatyshevVD@gmail.com
ORCID iD: 0000-0003-0643-8807

Vitaliy Dmitrievich Latyshev

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

Z. T. Fidarova

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0003-0934-6094

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

R. V. Ponomarev

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-1218-0796

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

N. V. Tsvetaeva

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-0977-215X

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

E. A. Mikhaylova

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-2449-2682

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

E. A. Lukina

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0002-8774-850X

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

E. N. Parovichnikova

National Medical Research Center for Hematology, Ministry of Health of Russia

ORCID iD: 0000-0001-6177-3566

4 Novyy Zykovskiy Proezd, Moscow 125167

Russian Federation

References

  1. Brodsky R.A. How I treat paroxysmal nocturnal hemoglobinuria. Blood 2021;137(10):1304–9. doi: 10.1182/blood.2019003812
  2. Rother R.P., Rollins S.A., Mojcik C.F. et al. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 2007;25(11):1256–64. doi: 10.1038/nbt1344
  3. Savchenko V.G., Lukina E.A., Mikhaylova E.A. et al. Clinical guidelines for the management of patients with paroxysmal nocturnal hemoglobinuria. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2022;67(3): 426–39. (In Russ.). doi: 10.35754/0234-5730-2022-67-3-426-439
  4. Hillmen P., Muus P., Röth A. et al. Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013;162:62–73. doi: 10.1111/bjh.12347
  5. Risitano A.M., Marotta S., Ricci P. et al. Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT. Front Immunol 2019;10:1157. doi: 10.3389/fimmu.2019.01157
  6. Debureaux P.E., Kulasekararaj A.G., Cacace F. et al. Categorizing hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: a multicenter real-life study. Bone Marrow Transplant 2021;56:2600–2. doi: 10.1038/s41409-021-01372-0
  7. Hill A., Rother R.P., Arnold L. et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica 2010;95(4):567–73. doi: 10.3324/haematol.2009.007229
  8. Risitano A.M., Notaro R., Marando L. et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood 2009;113:4094–100. doi: 10.1182/blood-2008-11-189944
  9. Risitano A.M., Notaro R., Luzzatto L. et al. Paroxysmal nocturnal hemoglobinuria – hemolysis before and after eculizumab. N Engl J Med 2010;363(23):2270–2. doi: 10.1056/NEJMc1010351
  10. Risitano A.M., Marando L., Seneca E., Rotoli B. Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab. Blood 2008;112:449–51. doi: 10.1182/blood-2008-04-151613
  11. Hillmen P., Szer J., Weitz I. et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2021;384:1028–37. doi: 10.1056/NEJMoa2029073
  12. Kulasekararaj A.G., Risitano A.M., Maciejewski J.P. et al. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab. Blood 2021;138:1928–38. doi: 10.1182/blood.2021011388
  13. Risitano A.M., Röth A., Soret J. et al. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial. Lancet Haematol 2021;8:e344–54. doi: 10.1016/S2352-3026(21)00028-4
  14. Peffault de Latour R., Fremeaux-Bacchi V., Porcher R. et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood 2015;125:775–83. doi: 10.1182/blood-2014-03-560540
  15. Tarasova Yu.V., Klimova O.U., Andreeva L.A. et al. Kinetic parameters of complement activation in patients with paroxysmal nocturnal hemoglobinuria during eculizumab therapy. Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2020;65(2):126–37. (In Russ.). doi: 10.35754/0234-5730-2020-65-2-126-137
  16. Nishimura J., Yamamoto M., Hayashi S. et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med 2014;370:632–9. doi: 10.1056/NEJMoa1311084
  17. Kelly R., Arnold L., Richards S. et al. Modification of the eculizumab dose to successfully manage intravascular breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria. Blood 2008;112:3441. doi: 10.1182/blood.V112.11.3441.3441
  18. Kulasekararaj A.G., Hill A., Rottinghaus S.T. et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: the 302 study. Blood 2019;133:540–9. doi: 10.1182/blood-2018-09-876805
  19. Fidarova Z.T., Mikhaylova E.A., Galtseva I.V. et al. The dynamics of paroxysmal nocturnal hemoglobinuria clone in patients with aplastic anemia in process of immune suppressive therapy. Klinichescheskaya laboratornaya diagnostika = Clinical Laboratory Diagnostics 2016;(8):490–4. (In Russ.). doi: 10.18821/0869-2084-2016-61-8-490-494
  20. Colden M.A., Kumar S., Munkhbileg B., Babushok D.V. Insights into the emergence of paroxysmal nocturnal hemoglobinuria. Front Immunol 2022;12:830172. doi: 10.3389/fimmu.2021.830172
  21. Luzzatto L., Notaro R. The “escape” model: a versatile mechanism for clonal expansion. Br J Haematol 2019;184:465–6. doi: 10.1111/bjh.15111
  22. Griffin M., Kulasekararaj A., Gandhi S. et al. Concurrent treatment of aplastic anemia/paroxysmal nocturnal hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience. Haematologica 2018;103:e345–7. doi: 10.3324/haematol.2017.183046
  23. Van Bijnen S.T.A., Ffrench M., Kruijt N. et al. Bone marrow histology in patients with a paroxysmal nocturnal hemoglobinuria clone correlated with clinical parameters. J Hematol 2013;6:71–82. doi: 10.1007/s12308-013-0179-7
  24. Sun L., Babushok D.V. Secondary myelodysplastic syndrome and leukemia in acquired aplastic anemia and paroxysmal nocturnal hemoglobinuria. Blood 2020;136:36–49. doi: 10.1182/blood.2019000940 25. Pagliuca S., Risitano A.M., De Fontbrune F.S. et al. Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis. Bone Marrow Transplant 2018;53:105–7. doi: 10.1038/bmt.2017.220
  25. Alashkar F., Dührsen U., Röth A. Horse anti-thymocyte globulin and eculizumab as concomitant therapeutic approach in an aplastic paroxysmal nocturnal hemoglobinuria patient: go or no-go? Eur J Haematol 2016;97:403–5. doi: 10.1111/ejh.12754
  26. Hill A., de Latour R.P., Kulasekararaj A.G. et al. Concomitant immunosuppressive therapy and eculizumab use in patients with paroxysmal nocturnal hemoglobinuria: an international PNH registry analysis. Acta Haematol 2023;146(1):1–13. doi: 10.1159/000526979
  27. Markiewicz M., Drozd-Sokolowska J., Biecek P. et al. Allogeneic hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: multicenter analysis by the Polish Adult Leukemia Group. Biol Blood Marrow Transplant 2020;26(10):1833–9. doi: 10.1016/j.bbmt.2020.05.024
  28. Liu L., Wang S., Jiang E. et al. Haploidentical vs matched sibling donor transplant for paroxysmal nocturnal haemoglobinuria: a multicenter study. Blood Cancer J 2022;12:92. doi: 10.1038/s41408-022-00682-w
  29. Schaap C.C.M., Heubel-Moenen F.C.J.I., Nur E. et al. Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: evaluation of treatment indications and outcomes. Eur J Haematol 2023;110:648–58. doi: 10.1111/ejh.13946
  30. De Latour R.P., Mary J.Y., Salanoubat C. et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood 2008;112:3099–106. doi: 10.1182/blood-2008-01-133918

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.